Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The primary objective of this study is to assess the frequency of reduction in grade (Grade 2 to 1) or resolution of imatinib-related chronic Grade 1 or Grade 2 non-hematologic AEs within 3 months after switch to dasatinib in patients with CP-CML.
Critère d'inclusion
- CP-CML patients with non hematologic low toxicity grade to imatinib